Sensorion announces the achievement of the primary endpoint in the Phase 2a clinical study evaluating SENS-401 in the indication of residual hearing preservation after cochlear implantation.

This Phase 2a study is a multi-center, randomized, controlled, open-label trial designed to assess the presence
of SENS-401 in the cochlea (perilymph) at therapeutic levels after 7 days of oral/bi-daily administration prior to cochlear implantation for moderately severe to profound hearing loss.

The study was developed in collaboration with Cochlear Limited, the world leader in implantable hearing solutions.

The presence of SENS-401 in the perilymph was confirmed in 100% of patients sampled, 7 days after the start of treatment, at a level consistent with potential therapeutic efficacy, confirming that the study's primary endpoint was met.

These results confirm that SENS-401, administered orally, crosses the labyrinthine barrier.

The Company expects to publish the full results of the study in the third half of 2024.

Nawal Ouzren, Chief Executive Officer of Sensorion, commented: "We look forward to the publication of the full data set from this study, including the secondary endpoints, which is expected later this year. These positive results are a key milestone in the development plan for SENS-401, a promising drug candidate whose efficacy in protecting against hearing loss in several strategic indications we aim to demonstrate.

Copyright (c) 2024 CercleFinance.com. All rights reserved.